Joshua Muia: Presenting Our Research on ADAMTS13/VWF Dysregulation in Sepsis at ISTH 2026
Joshua Muia, Associate Investigator at Versiti Blood Research Institute, shared on LinkedIn:
”Attending the International Society on Thrombosis and Haemostasis (ISTH) Congress is always one of the highlights of my year ISTH 2026, and I was especially excited to be in Paris, France this year.
I had the privilege of presenting our latest work on ADAMTS13/VWF dysregulation in sepsis on behalf of my graduate student, Olamilekan George.
Throughout my career, ISTH has played a transformative role by fostering an exceptional global network of colleagues, hosting a vibrant and scientifically outstanding congress, championing diversity and inclusivity, and providing awards and opportunities that enable early-career investigators to participate and grow.
The Society has created an environment where scientists at every stage can connect, collaborate, and thrive, and I am grateful to be part of this remarkable community.”
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 15:42Marc Carrier: Important New Data From the API-CAT Trial on Recurrent VTE During Extended Apixaban Therapy
-
Jul 13, 2026, 15:23Akshat Jain: 5 Key Clinical Takeaways from ISTH 2026
-
Jul 13, 2026, 15:15Alfonso J. Tafur: Insights on Periprocedural DOAC Management in Atrial Fibrillation at ISTH 2026
-
Jul 13, 2026, 14:42Bruno Pougault: The Global Momentum Behind Innovation in Thrombosis and Hemostasis
-
Jul 13, 2026, 14:34Julie Vassart: Optimizing DOAC Detection in an Evolving Anticoagulant Landscape at ISTH 2026
-
Jul 13, 2026, 13:57Heghine Khachatryan: The Diagnostic Dilemma of Non-Criteria Obstetric APS
-
Jul 13, 2026, 13:49Mitra Najafi: Translating Years of Innovation into Global Scientific Dialogue at ISTH 2026
-
Jul 13, 2026, 13:2810 Posts Not To Miss from ISTH 2026, Part 2
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026